Bayer (BAYN) Receives Consensus Recommendation of “Buy” from Analysts

Bayer (FRA:BAYN) has been assigned a consensus rating of “Buy” from the twenty-three analysts that are currently covering the stock, MarketBeat.com reports. One analyst has rated the stock with a sell rating, seven have issued a hold rating and fifteen have given a buy rating to the company. The average 12-month price objective among analysts that have issued a report on the stock in the last year is €116.95 ($139.23).

Several equities analysts have recently weighed in on BAYN shares. Cfra set a €110.00 ($130.95) target price on Bayer and gave the company a “buy” rating in a research report on Tuesday, April 10th. Barclays set a €95.00 ($113.10) target price on Bayer and gave the company a “sell” rating in a research report on Thursday, April 12th. Independent Research set a €102.00 ($121.43) target price on Bayer and gave the company a “neutral” rating in a research report on Thursday, March 1st. Commerzbank set a €111.00 ($132.14) target price on Bayer and gave the company a “buy” rating in a research report on Thursday, May 3rd. Finally, Sanford C. Bernstein set a €123.00 ($146.43) price objective on Bayer and gave the company a “buy” rating in a research report on Thursday, May 3rd.

Shares of BAYN traded up €0.46 ($0.55) during mid-day trading on Monday, hitting €102.56 ($122.10). 1,578,109 shares of the stock were exchanged. Bayer has a 52-week low of €91.58 ($109.02) and a 52-week high of €123.82 ($147.40).



About Bayer

Bayer Aktiengesellschaft operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, Crop Science, and Animal Health segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents.

Analyst Recommendations for Bayer (FRA:BAYN)

Receive News & Ratings for Bayer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bayer and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply